Galaxy Digital Upsizes Stock Offering to Roughly $125 Million
By Robb M. Stewart
Galaxy Digital Holdings bumped up the size of a proposed equity raising to roughly $125 million, priced at a discount to the last closing price for the stock.
The digital asset and blockchain company, which has earmarked the proceeds of the bought deal public offering for working capital and general corporate purposes, said Tuesday it now plans to sell 2.35 million of its shares at 14 Canadian dollars ($10.31) each to underwriter Canaccord Genuity.
Earlier in the day, the company said it planned to offer 9.75 million shares through the bought deal financing, which would have raised about $100 million in gross proceeds.
Galaxy's shares last closed at C$16.05 in Toronto, up 55% so far this year.
The underwriter's option to buy additional shares from certain shareholders also was bumped up, to as many as 1.82 million shares from 1.5 million previously. The selling shareholders include Galaxy Group Investments.
The offering is set to close on or about Friday, Galaxy said.
Late last month, the company swung to a fourth-quarter net income of $301.5 million from a year-earlier loss of $288.8 million as fee revenue and lending and staking revenue each more than doubled.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
April 09, 2024 09:55 ET (13:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks